⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kite Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Kite Pharma
↗Santa Monica, USA
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with a singular focus on cell therapy to treat and cure cancer. As a leader in the field, Kite has developed and commercialized pioneering CAR T-cell therapies that harness the patient's own immune system to target and eliminate cancer cells.
Following its acquisition by Gilead Sciences in 2017, Kite has leveraged robust global infrastructure to expand its manufacturing network and clinical reach. The company is dedicated to advancing next-generation cell therapy technologies, including research into solid tumors and novel modalities, while maintaining a strong commercial presence with flagship products like Yescarta and Tecartus.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1B-$2B
Founded:2009
Ownership:subsidiary
Status:acquired
STOCK
Exchange:NASDAQ
Ticker:GILD
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Cell therapy, CAR T-cell therapy
Active Trials:0
Trial Phases:-
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Parent Company:Gilead Sciences
Acquired By:Gilead Sciences (2017-10-01)
Key Partnerships:Amgen (Cancer Immunotherapy), Arcellx (Acquired for anito-cel)
COMPETITION
Position:Leader
Competitors:Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Novartis
LEADERSHIP
Key Executives:
Christi Shaw - CEO
Gallia Levy - SVP, Global Head of Development
LINKS
Website:kitepharma.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kite Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.